Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03836664 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03836664 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT03836664, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy (headache freedom at 2 hours) of Timolol 0.5% ophthalmic solution compared to placebo in acute treatment of migraine headache. And to assess the safety and tolerability of Timolol 0.5% ophthalmic solution in treatment of acute migraine headache.
Interventions
- DRUG Placebo
- DRUG Timolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2018-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03836664
The ClinicalTrials.gov registry entry for NCT03836664 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03836664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03836664 about?
NCT03836664 is a clinical study titled "A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine". The purpose of this study is to assess the efficacy (headache freedom at 2 hours) of Timolol 0.5% ophthalmic solution compared to placebo in acute treatment of migraine headache. And to assess the safety and tolerability of Timolol 0.5% ophthalmic solution in treatment of acute migraine headache.
What is the current status of trial NCT03836664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2017-02-27. Estimated completion is 2018-04-14.
What interventions are being tested in trial NCT03836664?
The interventions under investigation include: Placebo (DRUG), Timolol (DRUG).
Who is sponsoring clinical trial NCT03836664?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.